TrialBJU international2009
Final analysis of a phase II trial using sorafenib for metastatic castration-resistant prostate cancer.
Jeanny B Aragon-Ching et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
55 papers cite it
this paperpooled ittrialcites it